Citius OncologyNASDAQ: CTOR

Profile

Sector:

Healthcare

Country:

United States

IPO:

Website:

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$81.21 M
-97%vs. 3y high
41%vs. sector
-vs. 3y high
-vs. sector
-vs. 3y high
-vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 01 Nov 2024 13:30:00 GMT
$1.14-$0.04(-3.80%)

Dividend

No data over the past 3 years
No data over the past 3 years
No data over the past 3 years
No data over the past 3 years

Analysts recommendations

No data over the past 3 years

Institutional Ownership

Included in screeners

No data

What type of business is Citius Oncology?

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

What sector is Citius Oncology in?

Citius Oncology is in the Healthcare sector

What industry is Citius Oncology in?

Citius Oncology is in the Drug Manufacturers - Specialty & Generic industry

What country is Citius Oncology from?

Citius Oncology is headquartered in United States

Is Citius Oncology in the S&P 500?

No, Citius Oncology is not included in the S&P 500 index

Is Citius Oncology in the NASDAQ 100?

No, Citius Oncology is not included in the NASDAQ 100 index

Is Citius Oncology in the Dow Jones?

No, Citius Oncology is not included in the Dow Jones index

When was Citius Oncology the previous earnings report?

No data

When does Citius Oncology earnings report?

The next expected earnings date for Citius Oncology is 29 November 2024